The Emerging Role of Interleukin-1β in Autoinflammatory Diseases
- 398 Downloads
The autoinflammatory syndromes are a group of multisystem disorders characterized by recurrent episodes of fever and systemic inflammation affecting the eyes, joints, skin, and serosal surfaces in the absence of an immune reaction. Recent advances have revealed the importance of interleukin-1β, not only in the pathogenesis of many of these rare inherited diseases, but also in acquired diseases. The development and availability of anti–interleukin-1β therapeutics have introduced the possibility of proof-of-concept studies, which are likely to further widen this field.
KeywordsInterleukin-1 Inflammasome Autoinflammatory diseases Caspase-1 Cryopyrin NLRP3 CAPS Anakinra Rilonacept Canakinumab
Dr. Lachmann has received support from a European Union Framework 7 grant.
Dr. Lachmann has served as a consultant for Novartis and received honoraria and had travel/accommodations expenses covered by Novartis and Bristol-Myers Squibb.
Ms Lane reported no potential conflicts of interest relevant to this article.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 4.McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Medicine. 2006;3(8):1242–8.Google Scholar
- 19.Kile RL, Rusk HA. A case of cold urticaria with an unusual family history. JAMA. 1940;114:1067–8.Google Scholar
- 22.Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 2002;46:3340–8.PubMedCrossRefGoogle Scholar
- 28.Neven B, Marvillet I, Terrada C, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2010;62(1):258–67.PubMedCrossRefGoogle Scholar
- 29.Rigante D, Leone A, Marrocco R, et al. Long-term response after 6-year treatment with anakinra and onset of focal bone erosion in neonatal-onset multisystem inflammatory disease (NOMID/CINCA). Rheumatol Int. 2011 Jan 15. [Epub ahead of print].Google Scholar
- 33.Hoffman HM, Nadler DR, Brooks PW, et al. Rilonacept: Long-term safety profile in patients with cryopyrin-associated periodic syndromes (CAPS). Arthritis Rheum. 2009;60 Suppl 10:1237.Google Scholar
- 36.Meinzer U, Quartier P, Alexandra JF, et al. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011 Jan 28.Google Scholar
- 40.Alpay N, Sumnu A, Caliskan Y, et al. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int. 2010 Apr 13. [Epub ahead of print].Google Scholar
- 44.Rebelo SL, Bainbridge SE, Amel-Kashipaz MR, et al. Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum. 2006;54:2674–87.PubMedCrossRefGoogle Scholar
- 47.Pettersson T, Kantonen J, Matikainen S, et al. Setting up TRAPS. Ann Med. 2011 Feb 1. [Epub ahead of print].Google Scholar
- 66.Lovell DJ, Giannini EH, Kimura Y, et al. Preliminary evidence for sustained bioactivity of IL-1 Trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum. 2007;56(Suppl):S514–5.Google Scholar
- 67.Lovell DJ, Giannini EH, Kimura Y, et al. Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum. 2009;60(Suppl):S768.Google Scholar
- 68.Ruperto N, Quartier P, Wulffraat N, et al. Phase II trial with canakinumab (ACZ885) to evaluate safety and preliminary efficacy in children with systemic juvenile idiopathic arthritis (SJIA). Acta Paediatr. 2009;98:223–4.Google Scholar
- 72.Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011 May 3.Google Scholar
- 75.Boni-Schnetzler M, Thorne J, Parnaud G, et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab. 2008;93(10):4065–74.PubMedCrossRefGoogle Scholar